The previous results on the relationships between ERCC1 polymorphisms and clinical outcomes of platinum-based chemotherapy in NSCLC are inconclusive and even conflicting to each other, probably due to the complex gene interaction, environmental effects, different detection methods, sample sizes, or study designs. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.